옵티팜

153710KOSDAQ

53.8 / 100

Reference Date: 2026-09-08

Financial Score15.5 / 40

News Sentiment21.3 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

OptiPharm operates in multiple sectors including animal disease diagnosis, pharmaceutical development, bacteriophages, Medipig, and VLP vaccines, offering technology-driven services and products. The company differentiates itself through proprietary diagnostic systems, gene-editing technologies for transgenic animal development, and an efficient vaccine production system.

Number of Employees

79people

Average Salary

59.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.78Industry Average 1.200.0Point

2.3x industry avg (risky)

ROE

-9.48Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

10.79Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲13.4% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.2% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
코리, 북경 한미약품과 협력 강화…中 특화 의약품 공동개발
코리의 북경 한미약품과의 협력 강화로 중국 시장 특화 의약품 개발 및 헬스케어 제품 공동 사업화로 긍정적 영향 기대.

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 4,810Won52-week high 6,20052-week low 4,260

1-month return3.0Point

1m 0.94% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral반기보고서 (2026.06)2026-08-14
Neutral기업설명회(IR)개최2026-08-12